In addition, the immune checkpoint B7-H3 is upregulated in tissue samples from patients with BMs, suggesting that prostate cancer BMs have immunogenic characteristics distinct from those of the primary tumor (52). This evidence concerns the gene CD276 and Familial prostate cancer.